Pfizer Inc. PFE shares are trading lower by almost 1% on Monday as the company shared data from Phase 2b studies of ...

The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.

Roche Holding AG and Pfizer Inc. are aggressively advancing obesity and T2D pipelines to capture share in the surging GLP-1 ...

(PFE) has launched a new Phase 1 trial called “A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD STUDY…” to track how its experimental drug PF-07799544 moves through and leaves the body in healthy men.

Nausea and vomiting rates for the monthly injectable berobenatide came in close to benchmarks set by Novo Nordisk's weekly ...

The natural GLP-1 hormone survives in the body for only a few minutes before it is broken down. Drug developers overcome this ...

Pfizer’s latest share move reflects renewed attention on its label expansion, research pipeline, dividend profile, and ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene ...

Pfizer announced Friday that it is discontinuing development of its twice-daily weight loss pill danuglipron after a clinical trial showed "high rates" of adverse side effects among users. The ...

July 8 (Reuters) - Pfizer's (PFE.N), opens new tab respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a higher risk of pre-term or early births, according to a study ...